The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
|ClinicalTrials.gov Identifier: NCT00964236|
Recruitment Status : Completed
First Posted : August 24, 2009
Last Update Posted : January 4, 2018
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)|
|Study Start Date :||August 2009|
|Primary Completion Date :||August 2010|
|Study Completion Date :||August 2011|
Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Other Name: Kuvan
Healthy individuals without phenylketonuria (PKU).
- functional magnetic resonance imaging of the brain [ Time Frame: baseline, 4 week, & 6 month follow-up ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00964236
|United States, Missouri|
|University of Missouri|
|Columbia, Missouri, United States, 65211|
|Principal Investigator:||Shawn E Christ, Ph.D.||University of Missouri-Columbia|